A
Alexander Strasak
Researcher at Hoffmann-La Roche
Publications - 17
Citations - 541
Alexander Strasak is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Trastuzumab emtansine & Metastatic breast cancer. The author has an hindex of 8, co-authored 17 publications receiving 428 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez,Carlos H. Barrios,Wolfgang Eiermann,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Jennifer A. Petersen,Sven Stanzel,Alexander Strasak,Monika Patre,Paul Ellis +14 more
TL;DR: T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer.
Journal ArticleDOI
Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Paul Anthony Ellis,Carlos H. Barrios,Wolfgang Eiermann,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Alexander Strasak,Monika Patre,Edith A. Perez +12 more
TL;DR: Treatment with T-DM1 or with P + H + docetaxel or both has shown statistically significant increases in progression-free survival (PFS) and overall survival (OS) in phase II and III studies.
Journal ArticleDOI
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Ian E. Krop,Shanu Modi,Shanu Modi,Patricia LoRusso,Mark D. Pegram,Ellie Guardino,Betsy Althaus,Dan Lu,Alexander Strasak,Anthony D. Elias +9 more
TL;DR: Although there is potential for paclitaxel to be added to T-DM1 ± pertuzumab, peripheral neuropathy was common in this heavily pretreated population, and this regimen showed clinical activity.
Journal ArticleDOI
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
Miguel Martín,P. Fumoleau,J. A. Dewar,Joan Albanell,S. A. Limentani,Mario Campone,Jenny C. Chang,Monika Patre,Alexander Strasak,SL de Haas,J. Xu,José A. García-Sáenz +11 more
TL;DR: T-DM1 combined with docetaxel ± pertuzumab appeared efficacious in MBC or LABC; however, nearly half of patients experienced AEs requiring dose reductions with these T- DM1 combinations.
Journal ArticleDOI
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Shang-Chiung Chen,Angelica Quartino,Daniel Polhamus,Matthew M. Riggs,Jonathan French,Xin Wang,Shweta Vadhavkar,Melanie Smitt,Silke Hoersch,Alexander Strasak,Jin Yan Jin,Sandhya Girish,Chunze Li +12 more
TL;DR: Exposure-response relationships for efficacy were inconsistent across exposure metrics and HRs for survival in patients in the lowest T-DM1 exposure quartile vs. matched TPC-treated patients suggest that the approved T- DM1 dose is unlikely to be detrimental to patients with low exposure.